Rena Buckstein

In this insightful discussion, Amer Zeidan from Yale and Rena Buckstein from Sunnybrook share their expert views on treating lower-risk myelodysplastic syndromes (MDS). They highlight the importance of accurate diagnosis with bone marrow examinations and prognostic tools. Guillermo Garcia-Manero from MD Anderson dives into innovative treatments like erythropoiesis-stimulating agents and Luspatercept, while Andrew Brunner emphasizes the complexities of dosing. They advocate for improved strategies and collaboration to enhance patient care and outcomes.

Prof. Rena Buckstein, a leading hematology expert from Toronto, joins Prof. Moshe Mittelman to explore blood transfusions' critical role in managing myelodysplastic syndromes (MDS). They discuss the importance of personalized transfusion strategies tailored to individual health needs and hemoglobin levels. The conversation delves into the risks of iron overload from repeated transfusions and the benefits of iron chelation therapy. They aim to clarify misconceptions about transfusion limits and focus on enhancing the quality of life for MDS patients.

In this enlightening discussion, Professor Rena Buckstein, a leading expert in myelodysplastic syndromes, shares her insights on red blood cell transfusions and their impact on patient quality of life. She emphasizes that improvements in hemoglobin levels don't always correlate with better outcomes. The conversation explores evolving transfusion thresholds, with many patients advocating for higher limits. Additionally, Buckstein highlights the importance of factors like frailty and comorbidities, revealing how they influence both treatment efficiency and the financial aspects of care.